Skip to content

Effects of Light Treatment During Sleep on Young Men

Randomized, Placebo-Controlled Trial of Short Wavelength Light Administered Just Prior to Waking in Young Men

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00796939
Enrollment
30
Registered
2008-11-24
Start date
2006-03-31
Completion date
2006-10-31
Last updated
2015-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Delayed Sleep Phase Syndrome, Sleep

Brief summary

This study will determine if green light exposure during sleep is effective in reducing mild depression symptoms in young men.

Detailed description

The circadian rhythm is the human body's internal clock. It affects sleeping and wakefulness patterns. Some scientists theorize that a disruption of circadian rhythms, or other circadian abnormalities, can cause a depressed state. Light received through the eyes can alter the circadian rhythm, and sustained exposure to artificial bright light during the last half of usual sleep time can change the phase of the circadian rhythm. Several studies have found that exposure to bright white light in the morning hours is an effective treatment for depression, especially during the first week of depression treatment. Other studies have shown that green or blue light is preferable to yellow or red light in depression treatment. This study will expose young men to different types of light during the last part of their sleep cycle to determine whether the treatment is safe and tolerable and whether it reduces mood disturbance and depression. The study will also determine the light's effect on the production of luteinizing hormone (LH) and testosterone, hormones that may play a role in depression. Participation in this study will last 15 days. At the beginning of the study, participants will be provided with study materials and instructed in their use. These materials will include a wrist actigraph, which is a sleep and wakefulness monitoring device similar to a wristwatch; a binder containing instructions, questionnaires, and forms; and a light mask. Participants will be randomly assigned to receive a light mask with either intense green or dim red light. Participants will wear the wrist actigraph throughout the study. For the first 3 days of the study, participants will sleep normally and fill out questionnaires and a sleep diary. The questionnaires will measure mood, sleepiness, sleep quality, treatment effects, and sleep time preference. The sleep diary will be a record of time spent sleeping, time it takes to fall asleep, number of times waking during the night, and similar measures. Starting on the third night, participants will wear the light mask when sleeping. Every day participants will fill out the questionnaires and sleep diary, and they will contact the study investigators to ensure compliance and to ask any questions. Participants will also provide saliva and urine samples once at the beginning and once at the end of the study. These samples will be used to test for testosterone and LH, respectively.

Interventions

DEVICEGreen light mask

Participants will receive approximately 10,000 lux from green light-emitting diodes.

DEVICERed Light Mask

Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.

Sponsors

National Institute of Mental Health (NIMH)
CollaboratorNIH
University of California, San Diego
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
25 Years to 60 Years
Healthy volunteers
Yes

Exclusion criteria

* Presence of clinical depression * Presence of a sleep disorder

Design outcomes

Primary

MeasureTime frame
Safety, measured through the Systematic Assessment for Treatment Emergent Effects (SAFTEE) questionnaireMeasured on Days 3 and 15
Tolerability, measured through compliance reportsMeasured daily for the length of the study
Mood disturbance, measured on the Quick Inventory of Depressive Symptomology-Self Report (QIDS-SR)Measured on Days 3 and 15

Secondary

MeasureTime frame
Sleep diaryMeasured daily for the duration of the study
Testosterone, measured through saliva analysisMeasured on Days 3 and 13
Mood visual analog scaleMeasured daily for the duration of the study
Luteinizing hormone, measured through urinalysisMeasured on Days 3 and 13

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026